bronchitis vs pneumonia goroll 2009
TRANSCRIPT
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 1/47
Bronchitis-Pneumonia
"
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 2/47
4 Questions:
(a) Bronchitis or Pneumonia?
(b) Is a diagnostic workup indicated?(c) Are antibiotics indicated(d) Is hospital admission necessary?
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 3/47
Bronchitis or Pneumonia?
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 4/47
Symptoms are similar
may all be present in both entities: Cough (productive or nonproductive),
Fever, chest discomfort, and fatigue.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 5/47
Classic symptoms
³Classic´ pneumococcal pneumonia:o sudden chill -> o f ever, pleuritic pain, o
productive cough (rusty sputum). The ³atypical pneumonia´ ( Mycoplasma or Chlamydia):o sore throat and headache ->o nonproductive cough and dyspnea.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 6/47
Signs
Pleuritis or dyspnea - tends to suggestpneumonia.
Evidence of consolidation is indicative of pneumonia but is present only in fewoutpatients.
Findings may be Misleading if underlyinglung disease.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 7/47
Even CXR is problematic
1.In bronchitis - Chronic lung disease can simulate new inf iltrates
2.In pneumonia -Dehydration can minimize radiographic abnormalities
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 8/47
Is a diagnostic workup indicated?
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 9/47
Diagnosis
URI ± predominant nasal discharge, sore throat, or ear pain.
LRI ± predominant cough. But Symptoms ± are unreliable to diff erentiate bronchitis
f rom pneumonia Signs - entirely normal vital signs (no tachypnea,
tachycardia, high f ever, hypothermia) decreases the probability of pneumonia in outpatients to less than 1%!
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 10/47
Workup
crackles ± are not specif ic ± can be in bronchitis too!
The classic f indings of lung consolidation:
1.dullness to percussion, 2.egophony, 3.bronchial breath soundso are more specif ic f or pneumonia - but f ound only in 25%
of patients
Signs with etiologic signif icance: Er ythema multif orme - Mycoplasma pneumonia, Conf usion - Legionella.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 11/47
CXR ± when to order? And Why?
If pneumonia is suspected, P A and lateral CXR is indicated.
1.to conf irm the diagnosis.
2.If pleural eff usion o poorer outcomeo thoracent esis should be per f ormed to assess f or the
presence of an empyema (Unless the pleural eff usion is minimal)
Additional labs are not necessar y (unless hospitalized).
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 12/47
Is hospital admission necessary?
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 13/47
PORT guidelines (NEJ M 1997;336:243)
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 14/47
PORT SCORE > 90 = Hospital
Score < 51: Risk Class I, 0.1-0.4% mortality. Outpatient
Score 51-70: Risk Class II, 0.6-0.7% mortality. Outpatient -------------------------------------------------------------------------------Score 71-90: Risk Class III, 0.9-2.8% mortality. Outpatient or inpatient -------------------------------------------------------------------------------Score 91-131: Risk Class IV, >2.8% mortality. Inpatient
Score > 130: Risk Class V, >>2.8% mortality. Inpatient
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 15/47
CURB 65 prediction rule
Conf usion, Uremia (blood urea nitrogen >20 mg/dL), Respirator y rate greater than 30 per minute, Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic,
and age 65 years or older.
0 - 1 risk f actors - mortality low (0.7% and 2.1%, respectively).
These rules per f orm poorly in extreme or unusual circumstances. (eg: 20yr bp low, tachycardia, hypoxia).
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 16/47
Are antibiotics indicated
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 17/47
Antibiotic Therapy
Pneumonia ±o Empiric Antibiotic Tx initially o treatment f or 10 - 14 days.
Acut e bronc hi t is - is usually of viral origin -
empiric use of antibiotics does not improve outcomes!!!
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 18/47
Rule: Acute Bronchitis ± No Abx!
Most cases are viral Spontaneous resolution 1-2 weeks with or w/o Tx Overprescription of antibiotics in this population
is a major source of resistance. Also if Abx - X2 risk f or an individual of later
contracting a resistant inf ection!
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 19/47
Exception to the rule:
1.antibiotics are indicated f or COPD patients with acute exacerbation:
2.severe underlying disease (eg, congestive heart f ailure)
3.patients who are symptomatic f or more than 10 days1.Mycoplasma inf ection becomes a greater possibility. 2.P er t ussis ³ ³ ³
If an ant ibiot ic is t o be used, a macrolide is areasonable first c hoice!
because the macrolides are ac t ive against mycoplasmal and c hlamydial and B per t ussis.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 20/47
Bordetella pertussis:
Young adults (childhood immunity wanes af ter 15-20 yrs )
25% of patients with bronchitis lasting 2 weeks or more. three phases of disease:
o cat arr hal phase - rhinorrhea, low-grade f ever, and mild congestion
-1 to 2 weeks.o paroxysmal phase severe paroxysms of nonproductive cough,
with 10-30 coughs in a row. 2 to 4 weeks Posttussive syncope and vomiting. the characteristic ³whoop´ is absent in adults
o convalescent phase ± symptoms gradually resolve during the next
1 to 3 months. A single elevated pertussis serology has been
advocated as a rapid means of diagnosing pertussis.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 21/47
Pertusis Tx
Antibiotics are advocated if the f irst 4 weeks of illness (still inf ective).
The pref erred drugs are the f ollowing: Er ythromycin: 500mg X4/d - 14 days
Azithromycin: 500 mg day 1- then 250 mg f or 4additional days
Clarithromycin: 500mgX 2/d - 7 days Alternative: Resprim (800/160) X 2/d - 14 days
o TMP-SMZ - not usef ul in mycoplasmal inf ectionso Doxycycline ± not usef ul f or Pertussis
- Amoxicillin ± not so usef ul f or pertusis or mycoplasma
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 22/47
±
.138.5 ±
.2" ±.
.3:.13-5 .2, COPD .338.5
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 23/47
()
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 24/47
Tx f or persons less than 60 years old: S. pneumoniae, Mycoplasma, Chlamydia,Legionella. Covered with:
Er ythromycin 500 mg X 4/d = f irst-line. or Azithromycin 500 mg on day 1, f ollowed by 250 mg daily f or 4 days,
or Clarithromycin 500 mg twice daily f or 10 days
Second-line: doxycycline (100 mg twice daily).
Respirator y f luoroquinolones: levof loxacin (T AV ANIC 500 mg), moxif loxacin (MEG AXIN 400 mg) = X 1/day.
Older quinolones (e.g., ciprof loxacin) = less activity against the pneumoco = not recommended.
Penicillins /cephalosporins - not cover atypical pneum.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 25/47
Older Adults (>60) and Patients with Comorbidities:. S.pneumoniae remains the most common BUT: H. inf luenzae, M. catarrhalis, and other gram-negative
are possibilities. New Evidence: Mycoplasma and Chlamydiastill important!
also f or patients with recent (within 3 months) exposure to antibiotics (pneumococal resistance).
first-line: is a 2nd-generation macrolide (azithromycin or clarithromycin)
PLUS a high-dose -lactam: o amoxicillin, 1 g X 3/d, or o amoxicillin-clavulanate, 2 g twice daily.
o Alternative a respirator y f luoroquinolone.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 26/47
For hospitalized patients:First-line:3rd-generation cephalosporin (1 g of cef triaxone
daily) PLUS
a second-generation macrolidein a dose suff icient f or Legionella inf ection:azithromycin 500 mg daily or clarithromycin 500 mg X2/d
Provides coverage f or resistant S. pneumoniae.
Therapy narrowed af ter diagnostic test results: such as Legionella urinar y antigen and blood cultures.
The alternative empiric treatment:
respirator y f luoroquinolone. concern about emerging resistance.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 27/47
penicillin resistance of pneumococci mutations in penicillin-binding proteins
30% intermediate resistance ([MIC] of 0.1 to 1.0 µg/mL),
10% are highly penicillin resistant (MIC >2.0 µg/mL).
These highly resistant are of ten cross-resistant to multiple antibiotics, including trimethoprim/sulf amethoxazole and er ythromycin.
Fluoroquinolone resistance has been ver y low in S.
pneumoniae (<2%); now increasing.
emphasize the need to vaccinate high-risk patients. more than 85% of resistant organisms are serotypes
contained in the 23-valent vaccine
80% by prevnar (year 2000).
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 28/47
Monitoring
PORT study: temperature, RR, HR, and BP - reliable measures of stability.
average: ³normal´ vital signs at 3 days af ter hospitalization Of ten: Completely af ebrile: 6 days.
Repeating CXR at f requent intervals is wastef ul. particularly true of pneumocc or Legionella - still show an
inf iltrate a months later.
However, when worsening or f ever not resolving, CXR f or complications (abscess and empyema)
unusual or resistant organisms should be considered in these patients and antibiotic therapy appropriately adjusted.
More than 50% of patients with pneumonia continue to re ort f ati ue and cou h 1 month af ter dia nosis
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 29/47
Pneumococcal and Flu Vaccinepneumococcal vaccine 23 capsular types of pneumococci, which
together account f or about 90% of cases.
Indications: recover y f rom C AP, elderly (older than 65 years), CHF or COPD/ ASTHM A, are immunosuppressed, or have undergone splenectomy.
One-time revaccination af ter 5 years is recommended f or:immunosuppressed , f unctional asplenia, and elderly persons who received the initial vaccination bef ore age 65 years.
inf luenza vaccine - inactivated virus,
modif ied each year to include prevalent strains of inf luenza A and B. Indications: all patients older than age 50, pregnant women, and the high-risk groups mentioned previously. C/I: Hypersensitivity to eggs .
**The vaccines may be given at the same time without an increase in side eff ects or decrease in immunogenicity.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 30/47
Pathogens
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 31/47
Gram-Positive Organisms
S treptococcus pneumoniae ±o 30% to 5 0% of all cases of bacterial pneumonia.
o especially young ambulatory patientso also acute exacerbations in COPDS taphylococcus aureus ±
o 10% of bacterial pneumonia
o most commonly follows a viral URI (influenza)o Patients - usually extremely ill.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 32/47
Gram-Negative Organisms
H . influenzae common cause of bronchitis in COPD Bronchitis ± untypeable H.Flu
Pneumonias - especially type B. CXR - Bronchopneumonia Complications are uncommon ± unless
COPD (hypoxia)
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 33/47
Gram-Negative Organisms
K lebsiella pneumoniae: In debilitated patients, especially
alcoholics,
usually - acute illness; Rarely, chronic pneumonitis. tissue necrosis -> hemoptysis, Abcess.
CXR - dense lobar consolidation,Sputum may appear dark red andmucoid (³currant jelly´ sputum).
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 34/47
Other Gram-Negative- Hospitally acquires Pneumonias
Rare in Ambulator y setting Patients: Chronic disease or elderly
and frequently have received antibiotic
therapy.1.Moraxella (Branhamella) cat arr halis.2.Bordet ella per t ussis.
3.Legionnaires' Disease
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 35/47
catarrhalis:)Branhamella(Moraxella
f lora - orophar ynx of normal hosts Usually underlying pulmonary disease Other risk fac t ors: Diabet es, alcoholism,
malignancy, and st eroid use mild and somet imes self-limi t ed CXR interstitial+/-air space inf iltrate.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 36/47
Bordetella pertussis:
Young adults (childhood immunity wanes af ter 15-20 yrs )
25% of patients with bronchitis lasting 2 weeks or more. three phases of disease:
o cat arr hal phase - rhinorrhea, low-grade f ever, and mild congestion
-1 to 2 weeks.o paroxysmal phase severe paroxysms of nonproductive cough,
with 10-30 coughs in a row. 2 to 4 weeks Posttussive syncope and vomiting. the characteristic ³whoop´ is absent in adults
o convalescent phase ± symptoms gradually resolve during the next
1 to 3 months. A single elevated pertussis serology has been
advocated as a rapid means of diagnosing pertussis.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 37/47
Legionnaires' Disease
in 5%-10% of all community-acquired pneumonias (upto 30% of severe cases)
inf ection is acquired by inhalation of aerosols or
contaminated water. Risk f actors:cigarette smoking, chronic lung disease, and immunosuppression.
Spectrum of clinical illness: f rom mild URI and
self -limited atypical pneumonia to multif ocal pneumonia and respirator y f ailure.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 38/47
Legionnaires' Disease (Cont)
short prodrome, then acutely high f ever, nonproductive cough, dyspnea,P leuri t ic c hest pain
E x t rapulmonary findings are uncommon but include: myocardi t is, pericardi t is, r habdomyolysis, and renal
dysfunc t ion. Diarr hea or confusion are of ten seen Relative bradycardia CXR - interstitial inf iltrates or areas of patchy
consolidation with a rapid progression. Legionella urinar y antigen is ver y sensitive f or disease
caused by L. pneumophila serogroup 1 (about 70% of all cases) and is easy to obtain.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 39/47
Mixed Flora ±Aspiration pneumonias
Aerobic & anaerobic streptococci, Bac t eroides, and Fusobac t erium.
Risk f actors: impaired consciousness
(drugs, anesthesia, alcohol, head trauma) and diminution of the gag ref lex.
Lung abscess and empyema are f airly
common complications - especially if therapy is delayed.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 40/47
Nonbacterial Organisms
Mycoplasma pneumoniae Chlamydia pneumoniae (TWAR). Viruses.
Psittacosis. Q Fever. F ungi and Other Opportunistic
Organisms.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 41/47
Mycoplasma pneumoniae
10% to 25% of community-acquired pneumonia. leading cause of the at ypical pneumonia and also a
cause of acute bronchitis in healthy adults. long incubation period begins with headache, sore throat, and malaise, then
progresses to a nonproductive cough. Signs - usually un-impressive
o ery thema mul t iforme, is highly correlated with Mycoplasmainf ection in the patient with pneumonia.
o Bullous myringitis ± not common
CXR - pat c hy peribronc hial infil t rat es Lab:
o CBC ± normalo C old agglut inins in 50%
Uncommon complications: hemolytic anemia, aseptic
meningitis, Guillain-Barré syndrome, and myopericarditis.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 42/47
Chlamydia pneumoniae - TWAR
10% to 20% of of community-acquired pneumonia
Also - acute bronchitis.
young adults The prodrome resembles Mycoplasma CXR - less extensive involvement
usually self -limited;
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 43/47
Viruses
the most common cause of acute bronchitis more than 80% of all cases!!! Viral pneumonia resembles an atypical
pneumonia
Common: inf luenza, adeno, RSV, parainf luenza.
immunocompromised ± CMV inf luenza pneumonia - f ever and myalgia,
mild or a f ulminant, Bacterial pneumonia (pneumococcal, staphylococcal) is a f requent complication.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 44/47
Psittacosis
C hlamydia group also responsible f or trachoma transmitted f rom parrots or other birds
Atypical pneumonia
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 45/47
Q Fever
C oxiella burnet ii unique among rickettsial inf ections in that
pneumonia is prominent, no rash is associated
spread is through inhalation of inf ected dust particles rather than by way of the bite of an insect.
reside principally in animals; human contact with
cattle, sheep,goats, or inf ected animal skin or skin products. Clinically ±
o atypical pneumonia o hepatitis occurs in upto 33% of patients.
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 46/47
F ungi & Other Opportunistics
Immunosuppressed patients - Aspergillus, C andida, or PCP
However, some f ungal inf ections may occur in immunocompetent hosts:o exposure to spore-containing dusts ± hist oplasmosis,
coccidioidomycosis
nonproductive cough, f lulike illness, liver or splenic enlargement, CXR - alveolar inf iltrates, sometimes hilar adenopathy;
f ungal pneumonia, is usually self -limited without treatment except in immunocompromised hosts
8/8/2019 Bronchitis vs Pneumonia Goroll 2009
http://slidepdf.com/reader/full/bronchitis-vs-pneumonia-goroll-2009 47/47
:
60 ().1150 X 2 ± 10 .2500 X 3-4 ± 10 .3100 X 2 ± 7 ("
)
60 , COPD:
.1500 X 2 ±10
.2875 X 2 ±10
.3- ±Tavanic (levof loxacine).
+